FDA Inks Class II Designation For Embryo Viability Tests
This article was originally published in The Gray Sheet
Executive Summary
The agency set a class II with special controls designation for assisted reproduction embryo image assessment systems in a Feb. 26 final order, following the de novo decision for Auxogyn’s Eeva system last summer.
You may also be interested in...
Testing For Toxicity In Fertility Treatment Technologies
US regulators are proposing makers of fertility assistant devices first test their products on mice embryos in the lab to better understand any potential toxicity risk to human embryos and the viability of the fetus.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.